Treatment results in renal transplant recipients with non-Hodgkin’s lymphoma

• Published in: Transplantation proceedings Vol. 35; no. 4; pp. 1404 - 1407
• Main Authors: Akcali, Z, Ozyilkan, O, Moray, G, Emiroglu, R, Haberal, M
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-2003
• Subjects: Adult; Cadaver; Female; Humans; Incidence; Kidney Transplantation - statistics & numerical data; Living Donors; Lymphoma, Non-Hodgkin - epidemiology; Lymphoma, Non-Hodgkin - mortality; Lymphoma, Non-Hodgkin - therapy; Male; Middle Aged; Postoperative Complications - epidemiology; Survival Analysis; Time Factors; Tissue Donors; Turkey - epidemiology; Turkey
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/S0041-1345(03)00359-2

The purpose of this study was to investigate the incidence of non-Hodgkin’s lymphoma (NHL), response to treatment, and survival time in renal transplant recipients at our center who developed this form of neoplasia. Between October 1985 and August 2002, 1077 renal transplantations were carried out at our center. The incidence of NHL after transplantation was 1.1% (12/1077). All patients had their immunosuppressive doses reduced after they were diagnosed with NHL. Complete remission was achieved in eight cases, and five of these individuals were still alive at the time of writing. The circumstances for each of the three deaths in this group were as follows: (1) progressive gastric adenocarcinoma 9 years after being diagnosed with NHL, (2) stage III NHL cured with chemotherapy, but died of infection 2 years after NHL diagnosis, and (3) recurrent intestinal lymphoma, with death during second line chemotherapy. Of the five survivors in the remission group, one had to return to hemodialysis. The four patients who did not enter remission all died. The median time from transplantation to diagnosis of NHL was 66 months. At the time of writing, the median survival time for the eight patients who achieved complete remission was 41.5 months. The study showed that treatment of localized disease (skin or intestinal NHL) with surgery and/or radiotherapy/chemotherapy leads to complete remission and long survival times; however, patients in remission are at risk for other causes of death.